Patheon Signs Three Year $18 Million Development Agreement with Boehringer Ingelheim

Share Article

Development agreement to benefit Patheon's Pharmaceutical Development Services business.

I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules.

Patheon, Inc. (TSX: PTI), a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that Boehringer Ingelheim, a leading globally operating pharmaceutical corporation, has awarded it two projects with combined revenue of more than $18 million over a three year period of time. The projects are both fixed-dose combination drugs in development for the treatment of the growing population of type II diabetics.

In commenting on the announcement, Mark Kontny, Patheon’s President of Pharmaceutical Development Services and Chief Scientific Officer said, “I am very gratified that Boehringer Ingelheim recognizes our expertise in formulating, scaling and successfully launching complex formulations such as these molecules. It is this kind of support and recognition that has enabled us to develop our market leading position in pharmaceutical development services. ”

###

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Wendy Wilson
Patheon
(919) 226-3316
Email >